Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Athersys, Inc is a biotechnology business based in the US. Athersys shares (ATHX) are listed on the NASDAQ and all prices are listed in US Dollars. Athersys employs 83 staff and has a trailing 12-month revenue of around USD$10,000.
|Latest market close||USD$1.77|
|52-week range||USD$1.13 - USD$4.38|
|50-day moving average||USD$2.0053|
|200-day moving average||USD$2.5288|
|Wall St. target price||USD$7.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.306|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||1.77|
|1 month (2020-11-06)||0.57%|
|3 months (2020-09-04)||-10.15%|
|6 months (2020-06-05)||-36.33%|
|1 year (2019-12-05)||36.15%|
|2 years (2018-12-04)||-5.35%|
|3 years (2017-12-05)||-4.32%|
|5 years (2015-12-04)||60.91%|
|Gross profit TTM||USD$-33,412,000|
|Return on assets TTM||-50.49%|
|Return on equity TTM||-114.86%|
|Market capitalisation||USD$353.4 million|
TTM: trailing 12 months
There are currently 24.2 million Athersys shares held short by investors – that's known as Athersys's "short interest". This figure is 1.9% up from 23.7 million last month.
There are a few different ways that this level of interest in shorting Athersys shares can be evaluated.
Athersys's "short interest ratio" (SIR) is the quantity of Athersys shares currently shorted divided by the average quantity of Athersys shares traded daily (recently around 2.0 million). Athersys's SIR currently stands at 12.37. In other words for every 100,000 Athersys shares traded daily on the market, roughly 12370 shares are currently held short.
However Athersys's short interest can also be evaluated against the total number of Athersys shares, or, against the total number of tradable Athersys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athersys's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Athersys shares in existence, roughly 120 shares are currently held short) or 0.1358% of the tradable shares (for every 100,000 tradable Athersys shares, roughly 136 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Athersys.
Find out more about how you can short Athersys stock.
We're not expecting Athersys to pay a dividend over the next 12 months.
Athersys's shares were split on 5 June 2007. This wouldn't directly have changed the overall worth of your Athersys shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Athersys shares which in turn could have impacted Athersys's share price.
Over the last 12 months, Athersys's shares have ranged in value from as little as $1.13 up to $4.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athersys's is -1.7463. This would suggest that Athersys's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Athersys has bucked the trend.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.